Study of the Efficacy of an Investigational Drug in Adult Patients With Non Small-Cell Lung Cancer (NSCLC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00034957
Recruitment Status : Completed
First Posted : May 3, 2002
Last Update Posted : February 16, 2012
Information provided by (Responsible Party):

Brief Summary:
The primary goal of the study is to evaluate an investigational drug's effectiveness as a treatment for Non small-cell lung cancer (NSCLC)

Condition or disease Intervention/treatment Phase
Carcinoma, Non-Small-Cell Lung Lung Neoplasms Drug: Investigational drug Phase 2

Study Type : Interventional  (Clinical Trial)
Primary Purpose: Treatment
Actual Primary Completion Date : October 2002
Actual Study Completion Date : October 2002

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lung Cancer

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Other specific inclusion/exclusion criteria may apply. In order to determine eligibility, further examination by the investigator is necessary.

Inclusion Criteria: Eligible patients must be at least 18 years of age with a diagnosis of NSCLC that has gotten worse during or after treatment with platinum-based chemotherapy. Patients must have at least one tumor that can be evaluated by the doctor during the investigational drug treatment. Any side-effects from prior chemotherapy must have subsided, and blood and urine tests must show adequate bone marrow, liver, and kidney function.

Exclusion Criteria: Any of the following will exclude patients from study participation: receipt of more than 1 prior regimen of chemotherapy for NSCLC (repeat of the same chemotherapy at different points in time count as 1 regimen). Irradiation to 25% or more of bone marrow, prior high dose chemotherapy with bone marrow or stem cell support, current participation in other clinical trials, pregnant or breast-feeding women, known HIV-positive or AIDS-related illness.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00034957

United States, California
Research Center
Berkeley, California, United States, 94704
Research Center
Greenbrae, California, United States, 94904-2007
Research Center
Los Angeles, California, United States, 90048
Research Center
Rancho Mirage, California, United States, 92270
United States, Illinois
Research Center
Chicago, Illinois, United States, 60637-1463
United States, Kentucky
Research Center
Louisville, Kentucky, United States, 40202
United States, Massachusetts
Research Center
West Boylston, Massachusetts, United States, 01583
United States, Michigan
Research Center
Ann Arbor, Michigan, United States, 48109
United States, New Hampshire
Research Center
Lebanon, New Hampshire, United States, 03756
United States, Tennessee
Research Center
Nashville, Tennessee, United States, 37232-6868
United States, Texas
Research Center
Arlington, Texas, United States, 76012
Research Center
Dallas, Texas, United States, 75390
Sponsors and Collaborators

Responsible Party: Pfizer Identifier: NCT00034957     History of Changes
Other Study ID Numbers: 196-ONC-0100-005
First Posted: May 3, 2002    Key Record Dates
Last Update Posted: February 16, 2012
Last Verified: February 2012

Keywords provided by Pfizer:

Additional relevant MeSH terms:
Carcinoma, Non-Small-Cell Lung
Lung Neoplasms
Carcinoma, Bronchogenic
Bronchial Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases